Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, talks unmet need in ...

Some couples are restructuring their registries and celebrations to support charitable causes close to their hearts.

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights the ...

Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...